A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB)

Ingrid A. Mayer, Aleix Prat, Daniel Egle, Sibel Blau, J. Alejandro Perez Fidalgo, Michael Gnant, Peter A. Fasching, Marco Colleoni, Antonio C. Wolff, Eric P. Winer, Christian F. Singer, Sara Hurvitz, Laura García Estevez, Peter A. Van Dam, Sherko Kummel, Christoph Mundhenke, Frankie Holmes, Naveen Babbar, Laure Charbonnier, Ivan Diaz-PadillaFlorian D. Vogl, Dalila Sellami, Carlos L. Arteaga

Simmons Comprehensive Cancer Center
Simmons Comprehensive Cancer Center - Administration - Directors Office - Administration

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Sort by
Weight
Alphabetically

A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB)

Fingerprint

Medicine & Life Sciences